Literature DB >> 6243930

Epstein-Barr virus antibodies in multiple sclerosis.

C V Sumaya, L W Myers, G W Ellison.   

Abstract

Serum antibody titers to Epstein-Barr virus (EBV), an agent that persists in a latent form after the initial infection, were determined in 157 patients with multiple sclerosis and in 81 control subjects. Two patients (1.3%) and five control subjects (6.2%) lacked antibodies to EBV. In the subjects with antibodies, the prevalence of high titers (greater than or equal to 1:160) was significantly greater in patients, 69 (44.5%), than in control subjects, 22 (28.9%). The geometric mean titer of antibodies to EBV was significantly higher in patients, 107.0, than in control subjects, 77.1. There was no association between antibody titers and duration or activity of the disease. These findings further support the contention that patients with multiple sclerosis have a general aberration of the immunological system.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6243930     DOI: 10.1001/archneur.1980.00500510052009

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  31 in total

1.  Multiple sclerosis and Epstein-Barr virus.

Authors:  Ruth Ann Marrie; Christina Wolfson
Journal:  Can J Infect Dis       Date:  2002-03

2.  Absence of Epstein-Barr virus RNA in multiple sclerosis as assessed by in situ hybridisation.

Authors:  D A Hilton; S Love; A Fletcher; J H Pringle
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-08       Impact factor: 10.154

3.  Seroepidemiological study of infectious mononucleosis in older patients.

Authors:  S M Kirov; K A Marsden; S Wongwanich
Journal:  J Clin Microbiol       Date:  1989-02       Impact factor: 5.948

4.  Comparison of the immune response to Epstein-Barr virus and cytomegalovirus in sera and synovial fluids of patients with rheumatoid arthritis.

Authors:  M Musiani; M Zerbini; S Ferri; M Plazzi; G Gentilomi; M La Placa
Journal:  Ann Rheum Dis       Date:  1987-11       Impact factor: 19.103

Review 5.  Progress, prospects, and problems in Epstein-Barr virus vaccine development.

Authors:  Henry H Balfour
Journal:  Curr Opin Virol       Date:  2014-03-15       Impact factor: 7.090

6.  Epstein-Barr virus-specific T cell therapy for progressive multiple sclerosis.

Authors:  Michael P Pender; Peter A Csurhes; Corey Smith; Nanette L Douglas; Michelle A Neller; Katherine K Matthews; Leone Beagley; Sweera Rehan; Pauline Crooks; Tracey J Hopkins; Stefan Blum; Kerryn A Green; Zara A Ioannides; Andrew Swayne; Blake T Aftab; Kaye D Hooper; Scott R Burrows; Kate M Thompson; Alan Coulthard; Rajiv Khanna
Journal:  JCI Insight       Date:  2018-11-15

Review 7.  [Multiple sclerosis and Epstein-Barr virus : new developments and perspectives].

Authors:  K Ruprecht
Journal:  Nervenarzt       Date:  2008-04       Impact factor: 1.214

8.  Immunological status to Epstein-Barr virus and cytomegalovirus in patients with genital condylomata.

Authors:  M Zerbini; M Musiani; G Gentilomi; S Costa; M G Poggi; M La Placa
Journal:  Eur J Epidemiol       Date:  1989-09       Impact factor: 8.082

9.  Multiple sclerosis in the Orkney and Shetland Islands. IV: Viral antibody titres and viral infections.

Authors:  D C Poskanzer; J L Sever; J L Sheridan; L B Prenney
Journal:  J Epidemiol Community Health       Date:  1980-12       Impact factor: 3.710

10.  The causal cascade to multiple sclerosis: a model for MS pathogenesis.

Authors:  Douglas S Goodin
Journal:  PLoS One       Date:  2009-02-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.